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Abstract
Proton beam irradiation is a form of advanced radiotherapy providing superior distributions of a low LET radiation dose
relative to that of photon therapy for the treatment of cancer. Even though this clinical treatment has been developing for
several decades, the proton radiobiology critical to the optimization of proton radiotherapy is far from being understood.
Proteomic changes were analyzed in human melanoma cells treated with a sublethal dose (3 Gy) of proton beam
irradiation. The results were compared with untreated cells. Two-dimensional electrophoresis was performed with mass
spectrometry to identify the proteins. At the dose of 3 Gy a minimal slowdown in proliferation rate was seen, as well as
some DNA damage. After allowing time for damage repair, the proteomic analysis was performed. In total 17 protein levels
were found to significantly (more than 1.5 times) change: 4 downregulated and 13 upregulated. Functionally, they represent
four categories: (i) DNA repair and RNA regulation (VCP, MVP, STRAP, FAB-2, Lamine A/C, GAPDH), (ii) cell survival and stress
response (STRAP, MCM7, Annexin 7, MVP, Caprin-1, PDCD6, VCP, HSP70), (iii) cell metabolism (TIM, GAPDH, VCP), and (iv)
cytoskeleton and motility (Moesin, Actinin 4, FAB-2, Vimentin, Annexin 7, Lamine A/C, Lamine B). A substantial decrease (2.3
x) was seen in the level of vimentin, a marker of epithelial to mesenchymal transition and the metastatic properties of
melanoma.
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Introduction
Proton therapy is used worldwide to treat several types of cancer
due to superior targeting and energy deposition [1,2]. Uveal
melanoma is especially well suited for this kind of radiotherapy, as
precise dose delivery is crucial to maintain eye function. In spite of
the fact that proton therapy is used clinically with great success,
not much is known about the biological effects of proton radiation.
A substantial body of data has been accumulated on the biological
effectiveness of proton radiation [3–13], and on some mechanisms
of proton-induced cell death [14–17], but many other biological
effects of the proton beam are unclear [1]. As proton irradiation is
considered to be low-LET radiation (,20 keV/mm), its biological
effects are assumed to be similar to those induced by photon
radiation. However, there is some experimental data demonstrat-
ing that this is not always the case [1,18].
As a stressor and a factor in cell death, proton radiation, as with
other types of radiation, induces DNA damage, followed by DNA
repair and a cellular stress response cascade. However, in
comparison with photon radiation, proton therapy has been
observed to be more effective against photon-radioresistant cell
lines [4,7,12,19] and different DNA repair responses were
triggered, e.g. no ATR (ataxia-telangiectasia and Rad3-related
protein kinases) activation being observed [20]. In terms of DNA
damage, there was a prevalence of oxidative base damage [14],
more double strand breaks [21–23] and larger DNA repair foci
[24,25]. Apoptosis was induced at doses above 10 Gy [14,17] and
cell cycle arrest in the G2-M phase was observed [11].
Interestingly, a differential oxidative stress response gene expres-
sion was recorded [16,18].
Several cellular signaling cascades were induced by proton
irradiation. For example, in PC3 cells irradiated with 10 Gy, it
induced the cell cycle checkpoint ataxia-telangiectasia, mutated
gene (ATM) and its downstream targets, such as p53, p21, and
bax-a (Bcl-2–associat GTPase KRas protein and cyclin F, in
contrast to gamma radiation which upregulates cell cycle blockers,
such as Cyclin-dependent kinase inhibitor 2A [26]. p38, c-Jun N-
terminal kinases (JNK) and Mitogen-activated protein kinases
(MAP) signaling turned out to be crucial for proton irradiation–
induced apoptosis, whereas pro-survival ERK (Extracellular
Signal-regulated Kinase) activation, although typical for gamma-
radiation, was absent after proton irradiation [1]. Other differ-
ences were also found in the regulation of angiogenesis, metastasis
and migration properties, and inflammation [1].
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The goal of this study was to characterize the cellular response
to a sublethal dose of proton beam irradiation in a comprehensive
way at protein level. Proteomic analysis was performed using BLM
cells irradiated with 3 Gy of a 60 keV proton beam, passaged for
28–35 days to allow cellular repair. Our hypothesis was that a low
dose of proton beam irradiation affects the proteins implicated in
DNA repair, cellular stress response and survival even as a delayed
outcome of proton beam irradiation. A significant (more than 1.5




Human melanoma BLM is a highly metastasizing cell line. It
was derived from a lung metastasis of the human melanoma Bro
subline implanted in a nude mouse as earlier described [27,28]
and was cultured in an RPMI medium with 10% fetal bovine
serum and antibiotics. The BLM cells were a kind gift from Prof.
Martine J. Jager from Leiden University.
Proton Beam Irradiation
Cells in suspension in phosphate buffer saline (PBS) at 16106
cells/ml were transported on ice to the proton beam facility.
1.5 ml of the cell suspension was irradiated at RT in an Eppendorf
vial placed in a positioning holder. The source of the 58 MeV
proton beam was the AIC-144 cyclotron at The Institute of
Nuclear Physics, Polish Academy of Sciences, Kraków. The cells
were irradiated with the dose of 3.0 Gy (CGE). The dose rate was
0.15 Gy/s. Irradiated cells were transferred to the medium and
plated at 16105 cell/ml in 10 cm Petri dishes. After 7 passages of
irradiated BLM cells (4–5 weeks in culture after irradiation), they
were isolated and were used for proteomic analysis. Non-irradiated
BLM cells served as the control.
Cell Growth and Comet Assay
For the proliferation assay, 1,000 or 5,000 cells were seeded in
each well of a 96-well plate. At selected time points cells were
removed by trypsin, stained with trypan blue and the number of
living cells was counted using a Burker cytometer. The level of
DNA damage was determined by the electrophoresis of single cells
in agarose gel as earlier described [29,30]. Briefly, the cell
suspension was mixed with low melting point agarose, set on slides,
lysed and neutralized in appropriate buffers. Electrophoresis was
performed at 23 V (0.74 V/cm, 300 mA) for 30 min at 4uC. All
stages of the experiment were carried out in the dark to eliminate
any extra DNA damages. Prior to analysis the slides were stained
with propidium iodide (2.5 mg/ml). The analysis of DNA damage
was carried out with COMET PLUS 2.9 software (Comet Plus,
Theta System Gmbh, Germany). The percentage content of DNA
in the comet’s tail (TDC) was determined from 100 random
images of comets per slide. The analysis was done in two
replicates.
Proteomic Analysis
Sample preparation. The cells were washed two times in
1 ml of a wash solution (10 mM tris(hydroxymethyl)-amino-
methane (Tris), 5 mM magnesium acetate, pH 8.0) and centri-
fuged at 400 g for 10 min at 20uC. The cell pellet was lysed in an
ice-cold buffer that contained 7 M urea, 2 M thiourea, 4% 3-[(3-
cholamidopropyl) dimethylammonio] -1-propanesulfonate
(CHAPS), 40 mM Tris pH 8.5, 65 mM Dithiothreitol (DTT),
1 mM EDTA and 1 mM phenylmethylsulphonyl fluoride. Cell
disruption was achieved by sonication at 320 W, 20 kHz, 30 s
ON/30 s OFF, two times for 10 minutes with Bioruptor UCD-200
(Diogenode, Liege, Belgium). The cell lysate was centrifuged at 15
000 g for 30 min at 12uC to remove debris. Proteins were
precipitated using methanol and chloroform according to Wessel
and Flügge [31]. The protein pellet was solubilized in a
rehydration buffer that was composed of 7 M urea, 2 M thiourea,
2% CHAPS, 0.002% bromophenol blue, 0.5% immobilized pH
gradient (IPG) buffer and 20 mM DTT (the IPG buffer and DTT
were added just before use). Protein concentration was measured
by Bradford assay [32].
Two-dimensional electrophoresis. Isoelectric focusing
(IEF) was carried out with an Ettan IPGphor 3 IEF System (GE
Healthcare, Uppsala, Sweden). 24-cm strips with an immobilized
pH 3–10 nonlinear gradient (GE Healthcare) were passively
rehydrated for 16 h with 450 ml rehydration buffer containing
200 mg of total protein. The IEF was performed at 50 mA/strip for
80 000 Vh at 20uC. Prior to Sodium dodecyl sulfate -
Polyacrylamide gel electrophoresis the IPG strips were equilibrat-
ed using a two-step procedure, each being gently shaken for
10 min in a 75 mM Tris–HCl pH 8.8 buffer that contained 30%
glycerol, 6 M urea and 2% SDS. In the first step, the proteins were
reduced by the addition of 1% DTT to the buffer. In the second,
they were alkylated with 2.5% iodoacetamide. After IEF the
proteins were separated on 12.5% polyacrylamide gels (255 ? 296 ?
1 ? mm). The gels were cast using an Ettan DALTsix Gel Caster
(GE Healthcare). Electrophoresis was performed on an Ettan
DALTsix Large Vertical System (GE Healthcare) at 2 W/gel for
45 min and 16 W/gel for 3.5 h at 20uC. After electrophoresis, the
gels were fixed overnight in 50% methanol, 3% phosphoric acid
and stained with Colloidal Coomassie Blue according to the
following protocol. The gels were washed 3630 min with water.
In the first step of staining, the gels were incubated in a 400 ml
solution consisting of 34% methanol, 3% phosphoric acid and
17% ammonium sulfate. After 1 hour, 140 mg Coomassie Blue G-
250 was added to each gel and incubated for the next 5 days.
Before scanning on ImageScanner III (GE Healthcare, Uppsala,
Sweden) the gels were washed 3630 minutes with water. The gel
images were analyzed by ImageMaster 2D Platinum v 7.0 (GE
Healthcare).
Protein identification by mass spectrometry. To identify
the content of the protein spots of interest, the gel pieces were
manually excised, destained at 37uC by washing several times in
25% and 50% acetonitrile in a 25 mM ammonium bicarbonate
buffer (NH4HCO3). The gel pieces were dehydrated in 100%
acetonitrile (ACN) and dried in a Speedvac for 5 min, then 15 mL
trypsin (Biocentrum) solution (10 ng/mL in 25 mM NH4HCO3,
pH 8.0) was added and incubated for 15 min. After that an
additional 20 mL of 25 mM NH4HCO3 was added. Digestion was
carried out overnight at 37uC. Peptides were extracted by
sonication and drying with 100% ACN. The extracts were
evaporated to dryness and resuspended in 2% ACN with 0,05%
TFA. Peptides were analyzed using the UltiMate 3000RS
LCnanoSystem (Dionex) coupled with a MicrOTOF-QII mass
spectrometer (Bruker) using nano online ESIsprayer.
To briefly describe the of peptide analysis, the peptides were
injected on a C18 precolumn (Acclaim PepMap Nano trap
Column) using 2% ACN with 0,05% TFA as the mobile phase.
They were further separated on a 15 cm675 mm RP column
(Acclaim PepMap 75 mm 100 Å Nano Series TM Column) using
gradient 2–40% ACN in 0.05% FA for 30 minutes. MS was
operated in standard DDA (data dependent acqusition) MS/MS
mode with fragmentation of the most intensive precursor ions.
The MS spectra measured were recalibrated using the fragment
ions of trypsin derived peptides. The Mascot Generic format (.mgf)
Proteomics of Proton Beam Irradiated Cells
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was generated by pre-processing the raw data with Data Analysis
4.0 software (Bruker, Germany). The resulting lists of peaks were
used to search the non-redundant protein database Swissprot with
the taxonomic restriction – Homo sapiens (20 321 sequences)
using an in-house Mascot server (v.2.3.0, Matrix Science, London,
UK). The following search parameters were applied: enzyme
specificity – trypsin, permitted number of missed cleavages –1,
fixed modification – carbamidomethylation (C), variable modifi-
cations – oxidation (M), phosphorylation (STY), methylation (DE),
protein mass – unrestricted, peptide mass tolerance – 620 ppm,
fragment mass tolerance – 60.05 Da.
Results
Cell Growth Inhibition and DNA Damage
3 Gy of proton beam irradiation slowed down cell growth in
culture by app. 15% (Fig. 1 A). Starting from day 4, the number of
viable cells in culture decreased. This is in agreement with the
increase in DNA damage shortly after the treatment (Fig. 1B,C).
The cells were kept in culture for several passages (4–5 weeks)
before the proteomic analysis was performed, in order to allow for
cellular repair.
Proteomic Analysis
The mean number of identified spots per gel was 1200 and the
average number of matches per gel was 860 (71%). 22 differential
spots were found which fulfilled the Student t-test (Table 1). A
representative spot pattern is depicted in Fig. 2. The protein
contents of all differential spots were identified by LC-MS/MS on
the basis of peptide mass matching following digestion with
trypsin, and their peptide sequences which were obtained in a
fragmentation process. The SwissProt accession numbers, the
abbreviated and full names of the proteins, their theoretical pI and
MW values are presented in Table 1. It also shows data from the
mass spectrometry analysis, such as their score and the protein
amino acid sequence coverage by matching peptides and the
number of unique peptides. For the majority the identification was
very reliable with a very high score. Only in the case of two spots
were two proteins identified where it was not possible to specify the
source of the difference. Finally, 17 regulated proteins were
identified, 4 of them being downregulated, and 13 upregulated in
the proton irradiated samples in comparison to the control group.
The protein which showed the most pronounced downregulation
after proton irradiation was vimentin, which was found in four
spots. Detailed analysis of the MS/MS spectra for vimentin
revealed differences in the methylation pattern of the protein
isoforms. In spot number 1 methylation was recognized at 7
glutamic acid residues (109, 134, 136, 151, 151, 153, 225), in spots
no. 2 and 3 only at glutamic acid in position 151, while in spot
number 5 no modification was found. Although methylation
typically occurs at lysine and arginine, there are also reports of the
important biological role of the methylation of glutamic acid
[33,34]. In Fig. 3 the differential spots are shown.
Discussion
Our initial hypothesis was that a sublethal dose of proton beam
irradiation would upregulate the proteins implicated in DNA
repair, inflammation, stress response and the regulation of survival
and, that it would possibly downregulate those connected to the
metabolism, or to protein production. However, the data revealed
a slightly different picture. First of all, relatively few protein levels
were changed after irradiation in comparison with ionizing
radiation [35,36]. Moreover, relatively few proteins engaged in
DNA repair were upregulated. These unexpected results may arise
from the long period given for recuperation after the irradiation
insult. Another unanticipated result is the lack of inflammation-
Figure 1. The effect of proton beam irradiation on BLM melanoma cells. A. Proliferation of BLM cells after proton beam irradiation with
doses 0 (open circle), 2 (cross), 3 (diamond) and 4 Gy (triangle). Cells were irradiated in suspension, and then plated in 96-well plates. B, C. DNA
damage in untreated (white bar), and irradiated with 3 Gy of proton beam (stripped bar) BLM cells are presented in terms of the percentage of DNA
that left the comet’s head and was found in the comet’s tail after electrophoresis (TDC).
doi:10.1371/journal.pone.0084621.g001
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related proteins, as well as the number of regulated proteins
connected to the cytoskeleton and motility.
A closer look at the functions of proteins’ regulation after proton
beam irradiation suggests that it is possible to classify them, simply
for streamlining purposes, into four groups: i) DNA repair and
stress, ii) proliferation and survival control, iii) metabolism and iv)
connected to motility and the cytoskeleton (Fig. 4). This is an
arbitrary classification, as some proteins have multiple functions
and can play a role in more than one group.
Allowing cells to undergo several passages in culture to repair
proton irradiation damage before carrying out the proteomic
analysis ensures that the effects seen are long-term. Even a low
dose of 3 Gy results in proteomic changes in the next generations
of cells.
Inducing DNA Repair and Stress Response
As expected after any kind of radiation treatment, proton beam
irradiation upregulated protein levels engaged in DNA repair,
such as MVP, Lamine A/C and Glyceraldehyde 3-phosphate
dehydrogenase (GADPH). The last one participates in DNA repair
via APE1 endonuclease [37]. What is more, the level of
Transitional endoplasmic reticulum ATPase (VCP), known to be
involved in chromatin associated degradation, was also increased.
These changes are consistent with DNA repair after radiation.
The primary known function of MVP (Major Vault Protein)
is multidrug resistance, but recent studies have demonstrated that
it is also engaged in transport mechanisms, signal transmission,
and the immune response. MVP plays a role in cytoplasmatic
signal transduction cascades, and is involved in signal transduction
through the nucleocytoplasmic transport of PTEN (nuclear
phosphatase and tensin homologue deleted on chromosome 10).
Nuclear PTEN plays a role in chromosome stability (reducing
spontaneous double strand breaks), DNA repair, cell cycle arrest
and cellular stability. MVP is engaged in the DNA repair
mechanism (nonhomologous end joining) by interaction with
Ku70/80. The level of MVP increased in response to various
DNA damaging agents including irradiation [38]. MVP is
recognized as a prognostic biomarker of radiotherapy resistance
[39].
Lamine A/C A-type lamins control the transcription and
degradation of proteins, play key roles in cell cycle regulation and
DNA double-strand break repair. Importantly, the proteins
regulated by A-type lamins– Rb family members, 53BP1 (Tumor
suppressor p53-binding protein 1), BRCA1(breast cancer type 1
susceptibility protein) and RAD51– exert tumor suppressor
functions, with their loss being associated with cancer susceptibility
[40]. High levels of lamin A/C are followed by stimulation of cell
growth, migration and invasion [41].
VCP (Transitional endoplasmic reticulum ATPase, or
p97 or Cdc48) is highly abundant, accounting for about 1% of
total cellular protein. Conserved hexameric p97 belongs to the
type II AAA+ (ATPases associated with diverse cellular activities)
family [42]. VCP is postulated to be an ubiquitin-selective
chaperone, whose key function is to disassemble protein complex-
es. VCP is involved in a wide variety of cellular activities e.g., cell
cycle, apoptosis, gene transcription, proteostasis, and DNA
damage response autophagy and the regulation of chromatine.
In response to UV, phosphorylated VCP modulates the function
of RNA polymerase [43].
Several proteins related to mRNA regulation increased after
proton beam irradiation. Caprin-1 (Cytoplasmic activation/
proliferation-associated protein-1), involved in stress granules,
and programmed cell death 6 (PDCD6) engaged in P-bodies were
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granules (SGs) are important for mRNA regulation upon stress,
inhibiting protein synthesis to conserve energy for the repair of
molecular damage. They contain mRNA and numerous proteins,
and their content is highly dynamic. SGs also are known to
modulate signaling balancing apoptosis and cell survival [44,45].
Interestingly, our results show the upregulation of G3BP1 and/or
HSP70 (Heat shock protein 70 kDa). Both these proteins are
tightly connected to stress granules, as HSP70 is directly correlated
with SG formation, and G3BP1 (RasGAP SH3-domain-binding
protein 1) is a protein regulating mRNA stability and stress granule
formation [44]. Furthermore, MVP and VCP are connected to
transcription regulation, and Serine-threonine kinase receptor-
associated protein (STRAP) and Far upstream element binding
protein 2 (FAB-2) are associated with mRNA regulation.
Cytoplasmic activation/proliferation-associated pro-
tein-1 (Caprin-1) is a cytoplasmic phosphoprotein. Caprin-1
binds G3BP-1 (RasGAP SH3 domain binding protein-1), in
cytoplasmic stress granules [46], formed in response to stress like
heat, arsenite, unfolded protein response or toxins. G3BP-1 is
marker for SGs, which stabilize specific mRNAs, control their
Figure 2. Representative 2D electrophoresis maps stained with Colloidal Commassie. The results obtained for each experimental group
are shown: control BLM cells (untreated) (A), 3 Gy proton beam irradiated BLM cells (B).
doi:10.1371/journal.pone.0084621.g002
Figure 3. The zoomed changes in the level of spots identified by MS in the two groups. Left panel – control group, Right panel –3 Gy
irradiated group. Spot numbers as listed in Table 1.
doi:10.1371/journal.pone.0084621.g003
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translation and degradation and also control apoptosis by
sequestering and nullifying apoptosis-promoting factors [47].
Overexpression of Caprin-1 induced the formation of cytoplasmic
stress granules. Caprin-1 directly and selectively binds mRNA for
c-Myc and cyclin D2 [46].
PDCD6 (programmed cell death protein 6, or apoptosis-
linked gene-2, ALG-2). PDCP6 interacts with PATL1, a
component of the P-body, which is a cytoplasmic non-membra-
nous granule composed of translation-inactive mRNAs and
proteins involved in mRNA decay. PDCP6 co-localizes also with
mRNA-decapping enzyme 1A, a marker of P-bodies [48]. PDCD6
in complex with Alix (ALG-2 (apoptosis-linked gene 2)-interacting
protein X, known also as AIP1 or p95) induces calcium-dependent
apoptosis and reduces tumorigenicity [49].
STRAP (Serine-threonine kinase receptor-associated
protein) plays a role in mRNA splicing and cap-independent
translation [50].
FAB-2/FBP-2 (Far upstream element binding protein 2
(FBP-2, KHSRP) belongs to the FBP family, engaged in
transcription mechanisms i.e. splicing, mRNA stabilization, and
degradation. FBPs are special transcription factors; they recognize
the ssFUSE, single strand DNA cis element located upstream of the
promoter of a target gene (e.g c-myc) and bind torsionally stressed
pre-existing single strand regions and up-regulate gene expression.
FBP2 can promote the decay of labile mRNA machinery or favor
the maturation of a select group of microRNA precursors. FBP2
serves as a component of both Drosha and Dicer complexes and
regulates the biogenesis of a subset of miRNAs [51,52].
Proliferation and Survival Control
The largest group of proteins affected by proton beam
irradiation in BLM cells is associated with the proliferation and
pro-survival response, including STRAP, MCM-7, Annexin 7,
MVP, Caprin-1, PDCD6, and VCP. However, it is not clear
whether the overall effect is pro-survival or pro-apoptotic.
STRAP (Serine-threonine kinase receptor-associated
protein), which regulates both transforming growth factor beta
(TGF-b) and p53 signaling [53], is localized in both the cytoplasm
and nucleus. On the one hand STRAP as regulator of
Phosphoinositide-dependent kinase-1 and Apoptosis signal-regu-
lating kinase 1, stimulates cell growth and can contribute to tumor
progression by blocking TGF-b-mediated signaling, but on the
other hand it potentiates p53-induced apoptosis through direct
interaction with p53. These findings suggest that STRAP might
have an ambivalent role in the regulation of cell growth [53].
However, the mechanism of STRAP regulation is not completely
understood [50]. STRAP also physically interacts with B-MYB. B-
myb is a member of the Myb family of transcription factors, which is
ubiquitously expressed and involved in controlling cell prolifera-
tion and differentiation [53].
MCM-7 (Minichromosome Maintenance Protein 7) is a
member of the group of protein complexes that are essential for
DNA replication licensing and the control of cell cycle progression
from the G1 to the S phase. MCM belongs to the family of AAA+
proteins. MCM7 overexpression and amplification occurs in
several human malignancies [54,55], although MCM7 takes part
in both oncogenic and tumor suppressor signaling pathways.
MCM7 binds Rb, p107, p130 proteins, which exert control over
the entry into the S phase of DNA replication and cellular
proliferation [56]. MCM7 also binds androgen receptor (AR)
which regulates cell growth and proliferation. MCM7 serves as a
co-transcriptional and co-translational enhancing factor of AR
[57]. A unique feature of the MCM7 genome is that it contains an
intronic cluster of miRNA in intron 13. These miRNAs shut down
the expression of multiple tumor suppressor genes like p21,
transcription factor E2F1, Bcl-2-like protein 11, PTEN [58].
PTEN deficiency causes Akt (Protein Kinase B, or PKB)
hyperactivition and in consequence tumor initiation and progres-
sion. MCM7 overexpreession fosters tumorigenesis in combination
with the action of miRNAs [59]. MCM7 is also involved in the
activation of the ATR-dependent S-phase checkpoint by agents
that induce DNA replication stress e.g. UV or X radiation [60].
Annexin A7 (ANXA7 or synexin) is a ubiquitously expressed
member of the multifunctional Ca/phospholipid-binding annexin
family. It shows Ca2+ dependent GTPase activity and is involved
in membrane fusion and exocytosis. Annexin A7 is a tumor
suppressor in human prostate and breast cancers. It overcomes
pathologic androgen-receptor (AR) dependent proliferation via
retinoblastoma protein (Rb1/p105) [61]. On the other hand
Annexin A7 correlates with tumor malignancy and lymph node
metastasis. High levels of Annexin A7 in a tumor correlate strongly
with poor survival of patients. Repression of Annexin A7 results in
increased levels of cell apoptosis, down-regulated cell proliferation,
inhibited cell motility ability, and decreased cell invasive capacity
[62].
Major vault protein, MVP. Recent studies have shown that
MVP can cooperate with Insulin-like Growth Factor 1 (IGF-1R) in
preventing apoptosis by upregulation of B-cell lymphoma 2 family
of proteins (Bcl-2) and downregulation of Bax. Tumor progression
and resistance to chemotherapy and radiotherapy may also be
activated through the suppression of Bax and upregulation of IGF-
1R, resulting in increased proliferation and reduced apoptosis
caused by upregulation of Bcl-2 and overexpression of altered p53
Figure 4. A diagram showing all proteins regulated in proton-
irradiated BLM cells. The level of 17 proteins changed (.1.56) in
comparison with control. Thirteen proteins were upregulated (in black)
and 4 were downregulated (in red). Here they are presented in four, not
exclusive, groups: i) DNA repair and stress, ii) proliferation and survival
control, iii) metabolic and iv) connected to motility and the
cytoskeleton. ACTN 4 - a Actinin 4, Caprin-1 - Cytoplasmic activation/
proliferation-associated protein-1, FAB-2 - Far upstream element
binding protein 2, G3BP1 - RasGAP SH3-domain-binding protein 1,
GADPH - Glyceraldehyde 3-phosphate dehydrogenase, MCM-7– Mini-
chromosome Maintenance Protein 7, Moesin - Actin-regulatory protein,
MVP - Major Vault Protein, PDCD6 - Programmed cell death 6, or
apoptosis-linked gene-2, STRAP - Serine-threonine kinase receptor-
associated protein, TIM - Triosephosphate isomerase, VCP – Transitional
endoplasmic reticulum ATPase.
doi:10.1371/journal.pone.0084621.g004
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[63]. It was also shown that MVP binds to COP1 (constitutively
photomorphogenic 1 ubiquitin ligase). Mammalian COP1 causes
prooncogene c-Jun proteasome-mediated degradation but COP1
can also act as a monomeric E3 ubiquitin ligase to directly
ubiquitinate tumor suppressor p53. Under unstressed conditions
MVP enters into direct physical contact with COP1 and suppress
c-Jun-mediated transcription of activator protein 1 (AP-1) path-
way. After UV irradiation, MVP becomes phosphorylated,
releases COP1, and does not inhibit the AP-1 transcription
anymore [64].
Cytoplasmic activation/proliferation-associated pro-
tein-1 (Caprin-1) level correlates with cellular proliferation
[65,66]. Suppression of the expression of human Caprin-1 resulted
in a slowing of the proliferation rate, due to a prolongation of the
G1 phase of the cell cycle [65]. The Caprin-1 gene is suppressed in
response to the overexpression of the p53 gene, which suggests that
this gene could be an important mediator of p53-dependent tumor
growth suppression [66].
PDCD6 (programmed cell death 6, or apoptosis-
linked gene-2, ALG-2) is a calcium-binding protein involved
in cell proliferation and death. PDCD6 can induce calcium-
dependent apoptosis and reduce tumorigenicity [67]. PDCD6 is
ubiquitously localized in the cytoplasm; however, PDCD6 is
translocated to the nucleus in response to DNA damage. PDCD6
is involved in the signaling cascade of the p53-responsive apoptotic
machinery [68]. PDCD6 also plays a significant role in modulating
cellular angiogenesis and it can inhibit tumor growth via the
suppression of tumor angiogenesis [69]. There are conflicting
reports concerning the level of PDCD6 in tumors. PDCD6
expression is up-regulated in lung cancer patients, while reduced
PDCD6 expression is observed in gastric cancer, ovarian cancer
tissues and cancer cell lines. Moreover, recent studies indicate that
PDCD6 has a synergic pro-apoptotic effect with anti-cancer drugs
through the activation of NF-kB pathway [70].
VCP (Transitional endoplasmic reticulum ATPase, or
p97 or Cdc48) is a substrate for protein tyrosine phosphatase
(PTPL1), which is important in cellular transformations [71].
PTPL1 can have either a pro-apoptotic effect (via the death
receptor, Fas) or an anti-apoptotic impact (via Proto-oncogene
tyrosine-protein kinase Src, Insulin-like growth factor 1 receptor,
Human Epidermal Growth Factor Receptor 2 kinases) depending
on the cellular context [43]. Elevated expression of VCP is
observed in certain types of cancer tissues, e.g., colorectal
carcinomas, pancreatic endocrine neoplasms, follicular thyroid
cancer, hepatocellular and lung carcinoma [72,73]. VCP increases
the protection of cells against apoptotic stimuli through activation
of the NFkB and Akt signaling pathways [74].
G3BP1 (RasGAP SH3-domain-binding protein 1) or
HSP70 have been observed, although it is not clear which one
gives the signal. G3BP1 is a protein regulating mRNA stability and
stress granule formation and HSP70 is often induced in stress.
Both proteins are connected to the cellular stress response. As
mentioned above, Caprin-1 binds G3BP-1 stress granules [46].
Downregulation of Glycolysis
We observed the downregulation of two glycolytic enzymes as a
result of proton beam irradiation, namely TIM and GADPH.
TIM and GADPH are enzymes catalyzing two consecutive
reactions of glycolysis, step 5 (conversion of dihydroxyacetone
phosphate to glyceraldehyde 3-phosphate by TIM) and step 6
(simultaneous phosphorylation and oxidation of glyceraldehyde-3-
phosphate to 1,3-biphosphoglycerate). GADPH is also involved in
membrane transport, tubulin bundling and cytoskeletal dynamics,
stem cell regulation and DNA repair. The downregulation of two
consecutive steps in glycolysis might lead to a switch to
mitochondrial oxidation for energy production and a less
oncogenic fenotype [75].
TIM (Triosephosphate isomerase) is a glycolytic enzyme
which catalyses the conversion of dihydroxyacetone phosphate to
glyceraldehyde 3-phosphate. Different isoformes of the protein
were found in melanoma [76]. In our study TIM was identified as
a phosphorylated form (at serine 58). Earlier proteomic studies
revealed TIM upregulation (1.6 fold change) in melanoma patients
[77].
GADPH (Glyceraldehyde 3-phosphate dehydrogenase)
is a glycolytic enzyme tightly regulated at both transcriptional and
posttranslational levels. GAPDH specifically catalyzes the simul-
taneous phosphorylation and oxidation of glyceraldehyde-3-
phosphate to 1,3-biphosphoglycerate. GAPDH is also involved
in membrane transport, tubulin bundling and cytoskeletal
dynamics. GAPDH interacts with tRNA and a transcription
factor Oct-1 implicated in stress responses, metabolic control, and
poised transcription states, regulates normal and pathological stem
cell function. Many factors such as calcium, insulin or hypoxia up-
regulate GAPDH expression. The level of GAPDH is elevated in
many cancers [78].
Paradoxical Changes in Motility and Cytoskeleton
In metastatic melanoma cells, many proteins connected to cell
motility, adhesion and migration are upregulated. For example,
matrix metalloproteinase-2 and integrin avb3 are implicated in
melanoma metastases and progression [79]. The BLM cell line,
used in this study, is a metastatic melanoma, widely studied for its
high invasive capabilities [28,79,80]. For example, the chemokine
receptors CXCR3 and CXCR4 were shown to be expressed in the
BLM cell line [80].
Proton ion irradiation decreased cell migration and invasion in
a dose-dependent manner, strongly inhibited matrix metalopro-
teinase-2 activity in highly aggressive HT1080 human fibrosarco-
ma cells in vitro, and significantly decreased pulmonary metastasis
in mouse osteosarcoma in vivo [81].
In the present work, several proteins known to influence cellular
motility were affected after proton beam irradiation. Most
distinctly, Vimentin was strongly downregulated, along with the
downregulation of Annexin 7, whereas Moesin, Lamine A/C,
Lamine B and a Actinin 4 were upregulated.
Moesin (Actin-regulatory protein moesin) belongs to the
ezrin/radixin/moesin (ERM) family which provides a regulated
linkage between the plasma membrane and the actin cytoskeleton.
Moesin plays an important role in cell motility by connecting the
actin cytoskeleton to a variety of membrane anchoring proteins.
Moesin is an essential mediator for actin cytoskeleton remodeling
[82]. Moesin controls the adhesion dependent activation of Rho
and subsequent myosin II contractility during 3D collagen
invasion by melanoma cells [83]. Increased moesin expression
also promotes the epithelial–mesenchymal transition (EMT) by
regulating adhesion and contractile elements for changes in actin
filament organization [84].
ACTN4 (a Actinin 4) is an actin-binding protein associated
with cell motility and metastasis in breast, colorectal, pancreatic,
hepatocellular carcinoma, and ovarian cancers. ACTN4 crosslinks
F-actin filaments into bundles to form filopodia. Overexpression of
ACTN4 increases the migratory potential of cells [85].
FAB-2/FBP-2 (Far upstream element binding protein 2
(FBP-2, KHSRP). FBPs are co-regulated with the microtubule
destabilizer, cytosolic phosphoprotein stathmin (known as onco-
protein 18). FBP-2 primarily supports migration in different
hepatocellular carcinoma cells [86].
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Lamins A/C and B type are the main constituents of a
polymeric network known as a nuclear lamina which plays a key
role in the maintenance of genome localization, structure and
function. Overexpression of Lamin A/C results in the stimulation
of cell growth, migration and invasion. This oncogenic behaviour
of lamin A/C is regulated through modulation of the PI3K/
AKT/PTEN signaling pathway [41]. Lamin A regulates actin
dynamics, and its overexpression leads to a loss of cell adhesion.
This in turn increases cell motility and consequently increases the
invasive potential of the tumor [87]. A-type lamins also influence
the activity of oncogene b-catenin (via the interaction of the
membrane protein emerin with the Wnt/b-catenin pathway)
which also points to a possible role of A-type lamins in tumor
progression [88]. In turn, B lamin deficiency is involved in the
development of prostate cancer. B-deficient microdomains corre-
late with prostate cancer cell line aggressiveness and increased cell
motility [89].
Annexin A7 (ANXA7 or synexin). Repression of Annexin A7
results in increased levels of cell apoptosis, down-regulated cell
proliferation, inhibited cell motility ability, and decreased cell
invasive capacity [62].
Vimentin is one of the most widely expressed mammalian
intermediate filament proteins. It is a multifunctional protein,
regulating several different physiological functions, such as the
structural integrity of cells and tissues, adhesion and migration,
signal transduction, apoptotic and immune defense and the
regulation of genomic DNA [90]. In the majority of cancers
vimentin is overexpressed and associated with a metastatic
phenotype and a poor prognosis for the disease outcome.
Vimentin is a marker, as well as a key factor in regulating
EMT, a critical event in the induction of cell motility [91]. Recent
studies have revealed that vimentin is not only a diagnostic marker
but also a hematogenous metastasis clinical predictor for
melanoma [92].
A decrease in vimentin may lead to diminished metastatic
potential. For example, in B16 melanoma cells treated with
cyclohexamide a decrease in vimentin mRNa was seen, together
with a decrease in the formation of lung metastastes in mice. What
is more, this effect was reversible [93]. Similarly, withaferin A
caused the dose-dependent inhibition of lung metastases in a
breast cancer model [94].
Post-translation modifications of vimentin, specifically phos-
phorylation, are especially important for vimentin functioning.
Vimentin contains a highly complex phosphorylation pattern
involving a multitude of kinase specific sites which are recognized
by many kinases, including Rho kinase, protein kinase C (PKC),
cGMP kinase, Yes kinase, Raf-1 kinase, PAK kinase, and Aurora
B kinase. Phosphorylation enhances the disassembly of vimentin
into nonfilamentous (monomeric, dimeric, and tetrameric) parti-
cles, shifting the equilibrium between polymeric and depolymer-
ized vimentin. Dephosphorylated vimentin exerts its influence on
motility, adhesion, cell signaling, and cell survival. Similarly,
phosphorylated, disassembled vimentin has been demonstrated to
enhance the recycling of integrins subjected to endocytosis to the
plasma membrane during cell migration [90]. The results of a
proteomic 2DE experiment on melanoma cells confirm the
multiisofomic pattern of vimentin [76]. It was attempted in the
present study to confirm the changes in the level of vimetin by
means of Western Blot analysis (data not shown), although the
results were not statistically significant. The antibody applied
(Vimentin (R28) Antibody #3932, Cell Signaling Technology)
recognizes a synthetic peptide of vimetin which includes arginine
at position 28. This residue is surrounded by serine and threonine
amino acids, which are very often modified (phosphorylated).
Because of the multiplicity of possible vimentin post-translational
modifications, which may alter the affinity of the antibody for a
protein, the Western Blot analysis is hampered especially in terms
of quantitative analysis.
A decrease in vimentin level, as well as in Annexin 7, might
suggest cell motility impairment, and decreased cell invasive
capacity [62]. However, other proteins involved in motility and
the cytoskeleton were upregulated. It is difficult, therefore, to assess
the overall effect on cellular motility and migration. These proteins
may change as the response of highly motile cells to stress, as part
of their prosurvival response.
Signalling Pathways Affected by Proton Beam Irradiation
Disturbances in several signaling pathways, such as MAPK-
ERK, RAS, AKT/PI3, G1/S Cyclin/Cyclin-dependent kinases,
p53, B-RAF are characteristic of melanoma progression [95,96].
These pathways are connected with the modulation of prolifer-
ation, survival, the cell cycle, and cell differentiation. It is not
surprising that some of the proteins upregulated after proton beam
irradiation are also involved in these signaling pathways, critical
for survival and proliferation (Table 2).
TGFb acts as a tumor-derived immunosuppressor, an inducer
of tumor mitogens, a promoter of carcinoma invasion, and a
trigger of prometastatic cytokine secretion [97]. Photon radiation
causes the upregulation of TGFb secretion into the microenvi-
ronment and can induce fibro- sis by promoting the excessive
synthesis of matrix components [98]. STRAP inhibits TGF-b
signalling by stabilizing the association between TGF-b receptors
and Smad7 or Smad3 (proteins that transduce extracellular signals
from transforming growth factor beta ligands to the nucleus)
[53,99,100]. The interaction of MCM7 with Rb is essential for
transforming the growth factor (TGF)-b-induced blockade of entry
into the S phase [56].
Table 2. Signaling pathways involving proteins upregulated
after sublethal proton beam irradiation.
Pathway Regulated proteins (reference)
MAPK MVP (Valenciano et al., 2012) [63]
AKT/PI3 MVP (Blanco-Aparicio et al., 2007) [103]
PDCD6 (Rho et al., 2012) [69]
VCP (Braun and Zischka, 2008) [74]
Lamin A/C (Kong et al., 2012) [41]
PTEN MVP (Lara et al., 2011) [104]
MCM-7 (Luo et al., 2011) [58], (Poliseno et al., 2010)
[59]
Lamin A/C (Kong et al., 2012) [41]
p-53 MVP (Lloret et al., 2009) [105]
STRAP (Seong et al., 2007) [106]
PDCD6 (Suzuki et al., 2012) [68]
Caprin-1 (Saffari et al., 2009) [66]
Cell cycle MCM-7, G1/S phase (Mukherjee et al., 2009) [56]
Caprin-1, G1/S phase (Wang et al., 2005) [65]
Caprin-1, cyclin D2 (Solomon S. et al., 2007) [46]
TGF-b STRAP (Seong et al., 2007) [106]
nFkB VCP (Braun and Zischka, 2008) [74]
PDCD6 (Park et al., 2012) [70]
doi:10.1371/journal.pone.0084621.t002
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The relatively low dose of 3 Gy used in our studies, the time
allowed for cell repair after irradiation might be the reasons we did
not see the induction of signaling pathways described by others
after proton irradiation, such as the direct apoptosis induction
pathways p38/JNK [26].
Comparison with other Melanoma Studies
Proteomic analysis of uveal melanoma from patients with
distant metastases has shown increased expression of vimentin and
TIM, among other proteins [77], in comparison to patients
without metastases. In metastases of uveal melanomas, several
proteins were found to be upregulated: Colony stimulating factor
2, Ficolin precursor, Haptoglobin -2 precursor, Hemopexin
precursor, a-1-antitrypsin precursor, a-1-antichymotrypsin pre-
cursor, Vitronectin precursor, and Down syndrome cell adhesion
molecule [101]. However, none of them were found to be
modulated in our experiments. Proteomic analysis of melanoma
metastases in comparison to primary tumors has shown upregula-
tion of several proteins, implicated as metastasis-related proteins,
such as lactate dehydrogenase, heat shock protein 90 KDa,
glucose transporter 1, Macrophage migration inhibitory factor,
Protein DJ-1, pyruvate kinase isozyme 2 and prohibitin-2 [102].
Again, none of these proteins were modulated in our study. Only
GADPH, elevated in metastasis, was downregulated after proton
beam irradiation in our cell line. Another comparative proteome
analysis of two genetically, very closely related, melanoma cell
lines with low- and high-metastatic potentials identified 42 proteins
with increased levels in highly metastatic melanoma cells, while 68
showed decreased levels [98]. Four of the proteins with increased
levels in highly metastatic melanoma cells were also seen in our
study: Vimentin and TIM levels decreased after proton beam
treatment, and STRAP and Actinin 4 increased.
Future work should cover other cancer cell lines, such as uveal
melanoma or prostate cancer, both of which respond well to
proton beam therapy. Perhaps proteomic analysis should also be
performed a shorter time after irradiation.
Conclusions
Proteomic analysis of the BLM melanoma cell line irradiated
with a low dose of 3 Gy of proton beam shows a significant (more
than 1.56change) upregulation of 13 proteins and downregulation
of 4 proteins. These proteins might be roughly grouped into four
categories by function: (i) DNA repair and RNA regulation (VCP,
MVP, STRAP, FAB-2, Lamine A/C, GAPDH), (ii) cell survival
and stress response (STRAP, MCM7, Annexin 7, MVP, Caprin-1,
PDCD6, VCP, HSP70), (iii) cell metabolism (TIM, GAPDH,
VCP), and (iv) cytoskeleton and motility (Moesin, Actinin 4, FAB-
2, Vimentin, Annexin 7, Lamine A/C, Lamine B). Of particular
interest is the substantial decrease (2.36) in vimentin, a marker of
EMT and of the metastatic properties of melanoma [92].
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al. (2007) Viability of a human melanoma cell after single and combined
treatment with fotemustine, dacarbazine, and proton irradiation. Ann N Y Acad
Sci 1095: 154–164.
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(2009) Moesin orchestrates cortical polarity of melanoma tumour cells to
initiate 3D invasion. J Cell Sci 122: 3492–3501.
84. Haynes J, Srivastava J, Madson N, Wittmann T, Barber DL (2011) Dynamic
actin remodeling during epithelial-mesenchymal transition depends on
increased moesin expression. Mol Biol Cell 22: 4750–4764.
Proteomics of Proton Beam Irradiated Cells
PLOS ONE | www.plosone.org 11 January 2014 | Volume 9 | Issue 1 | e84621
85. Sen S, Dong M, Kumar S (2009) Isoform-specific contributions of alpha-actinin
to glioma cell mechanobiology. PLoS One 4: e8427.
86. Malz M, Weber A, Singer S, Riehmer V, Bissinger M, et al. (2009)
Overexpression of far upstream element binding proteins: a mechanism
regulating proliferation and migration in liver cancer cells. Hepatology 50:
1130–1139.
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